| First Author | Junttila TT | Year | 2010 |
| Journal | Cancer Res | Volume | 70 |
| Issue | 11 | Pages | 4481-9 |
| PubMed ID | 20484044 | Mgi Jnum | J:160684 |
| Mgi Id | MGI:4454941 | Doi | 10.1158/0008-5472.CAN-09-3704 |
| Citation | Junttila TT, et al. (2010) Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res 70(11):4481-9 |
| abstractText | The enhancement of immune effector functions has been proposed as a potential strategy for increasing the efficacy of therapeutic antibodies. Here, we show that removing fucose from trastuzumab (Herceptin) increased its binding to FcgammaRIIIa, enhanced antibody-dependent cell-mediated cytotoxicity, and more than doubled the median progression-free survival when compared with conventional trastuzumab in treating preclinical models of HER2-amplified breast cancer. Our results show that afucosylated trastuzumab has superior efficacy in treating in vivo models of HER2-amplified breast cancer and support the development of effector function-enhanced antibodies for solid tumor therapy. |
